Notably, in our PDE4D knockout mice, the therapeutic effect of cinobufagin on AD was abolished, suggesting that the therapeutic efficacy of cinobufagin highly depends on the presence of PDE4D and indicating that PDE4D may be the primary, if not exclusive, functional target of cinobufagin. The gene discussed is PDE4D; the disease is Alzheimer disease.